The impact of aging on cancer vaccination

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness, caused by various age-related changes of the immune system. This includes lack of naïve T cells, defects in activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment. Although evidence exists that also natural killer (NK) and natural killer T (NKT) cells of the innate immune system change with age, comparison of various studies involving adaptive and innate immune responses in elderly and cancer patients, as well as cancer vaccination at young and old age in this review, indicates that also innate immune responses should be tested as a potential candidate to improve immunotherapy against cancer at older age.

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalCurrent Opinion in Immunology
Volume23
Issue number4
DOIs
StatePublished - Aug 2011

Fingerprint

Vaccination
T-Lymphocytes
Innate Immunity
Immune System
Neoplasms
Natural Killer T-Cells
Tumor Microenvironment
Viral Tumor Antigens
Adaptive Immunity
Antigen-Presenting Cells
Immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The impact of aging on cancer vaccination. / Gravekamp, Claudia.

In: Current Opinion in Immunology, Vol. 23, No. 4, 08.2011, p. 555-560.

Research output: Contribution to journalArticle

@article{c8150a6a89154ea68c0b5f7afd611cfe,
title = "The impact of aging on cancer vaccination",
abstract = "Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness, caused by various age-related changes of the immune system. This includes lack of na{\"i}ve T cells, defects in activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment. Although evidence exists that also natural killer (NK) and natural killer T (NKT) cells of the innate immune system change with age, comparison of various studies involving adaptive and innate immune responses in elderly and cancer patients, as well as cancer vaccination at young and old age in this review, indicates that also innate immune responses should be tested as a potential candidate to improve immunotherapy against cancer at older age.",
author = "Claudia Gravekamp",
year = "2011",
month = "8",
doi = "10.1016/j.coi.2011.05.003",
language = "English (US)",
volume = "23",
pages = "555--560",
journal = "Current Opinion in Immunology",
issn = "0952-7915",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - The impact of aging on cancer vaccination

AU - Gravekamp, Claudia

PY - 2011/8

Y1 - 2011/8

N2 - Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness, caused by various age-related changes of the immune system. This includes lack of naïve T cells, defects in activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment. Although evidence exists that also natural killer (NK) and natural killer T (NKT) cells of the innate immune system change with age, comparison of various studies involving adaptive and innate immune responses in elderly and cancer patients, as well as cancer vaccination at young and old age in this review, indicates that also innate immune responses should be tested as a potential candidate to improve immunotherapy against cancer at older age.

AB - Cancer vaccination is less effective at old than at young age, due to T cell unresponsiveness, caused by various age-related changes of the immune system. This includes lack of naïve T cells, defects in activation pathways of T cells and antigen-presenting cells (APC), and age-related changes in the tumor microenvironment. Although evidence exists that also natural killer (NK) and natural killer T (NKT) cells of the innate immune system change with age, comparison of various studies involving adaptive and innate immune responses in elderly and cancer patients, as well as cancer vaccination at young and old age in this review, indicates that also innate immune responses should be tested as a potential candidate to improve immunotherapy against cancer at older age.

UR - http://www.scopus.com/inward/record.url?scp=80052353920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052353920&partnerID=8YFLogxK

U2 - 10.1016/j.coi.2011.05.003

DO - 10.1016/j.coi.2011.05.003

M3 - Article

C2 - 21763118

AN - SCOPUS:80052353920

VL - 23

SP - 555

EP - 560

JO - Current Opinion in Immunology

JF - Current Opinion in Immunology

SN - 0952-7915

IS - 4

ER -